👀 Ones to watch: Undervalued stocks to buy before they report Q3 earningsSee Undervalued Stocks

Cosmo Pharmaceuticals NV (0RGI)

London
Currency in CHF
74.90
+20.40(+37.43%)
Closed
0RGI Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
74.6075.20
52 wk Range
58.1080.50
Prev. Close
54.5
Open
74.9
Day's Range
74.6-75.2
52 wk Range
58.1-80.5
Volume
124
Average Volume (3m)
613
1-Year Change
56.04%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
0RGI Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
103.15
Upside
+37.35%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield
Show more

COSMO Pharmaceuticals SA Company Profile

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, a submucosal injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers’ diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin SV MMX – IBS-D, a formulation that is in Phase III clinical trial to treat colonic infections and irritable bowel syndrome with diarrhoea; CB-03-10, an oral androgen receptor antagonist, which is in Phase I clinical trial for treatment solid tumors; CB-01-33 that is in preclinical studies for the treatment of bile acid diarrhea; and CB-01-35, an enema solution, which is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, RedHill Biopharma Ltd., Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Employees
319

Compare 0RGI to Peers and Sector

Metrics to compare
0RGI
Peers
Sector
Relationship
P/E Ratio
18.3x23.5x−0.6x
PEG Ratio
0.030.010.00
Price/Book
2.6x3.1x2.6x
Price / LTM Sales
6.9x2.6x3.2x
Upside (Analyst Target)
-8.1%49.1%
Fair Value Upside
Unlock10.1%7.2%Unlock

People Also Watch

121.60
MOVE
+0.33%
1,134.00
IFCN
-4.71%
13.80
MOZN
+0.29%
112.80
KOMN
-0.53%
387.00
SWTQ
-4.21%

FAQ

What Is the COSMO Pharma (0RGI) Stock Price Today?

The COSMO Pharma stock price today is 74.90

What Stock Exchange Does COSMO Pharma Trade On?

COSMO Pharma is listed and trades on the London stock exchange.

What Is the Stock Symbol for COSMO Pharma?

The stock symbol for COSMO Pharma is "0RGI."

Does COSMO Pharma Pay Dividends? What’s The Current Dividend Yield?

The dividend yield is 2.51%.

What Is the COSMO Pharma Market Cap?

As of today, COSMO Pharma market cap is 1.20B.

What is COSMO Pharma Earnings Per Share?

The COSMO Pharma EPS is 4.33.

From a Technical Analysis Perspective, Is 0RGI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.